Two years of ADT reduce the risk of metastases in patients undergoing post-prostatectomy radiotherapy
The first results from the RADICALS-HD trial were presented at ESMO22. To reduce the risk of metastasis in patients with prostate cancer undergoing post-prostatectomy radiotherapy, results indicate that two years of androgen deprivation therapy is better than six months. Let Chris Parker, Professor at the Royal Marsden Hospital, UK, explain what impact the results have on the future treatment of prostate cancer.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.